




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :  A61B 5/05, A61M 31/00		A1	(11) International Publication Number: <b>WO 95/28878</b>  (43) International Publication Date: 2 November 1995 (02.11.95)
(21) International Application Number: PCT/US95/04824 (22) International Filing Date: 24 April 1995 (24.04.95)  (30) Priority Data: 08/231,800 25 April 1994 (25.04.94) US		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>	
(71) Applicant: MINIMED INC. [US/US]; 12744 San Fernando Road, Sylmar, CA 91342 (US).  (72) Inventors: LORD, Peter, C.; 25505 Old Course Way, Santa Clarita, CA 91355 (US). COLMAN, Fredric, C.; 16339 Shamhart Drive, Granada Hills, CA 91344 (US).  (74) Agent: LOWRY, Stuart, O.; Kelly, Bauersfeld & Lowry, Suite 1650, 6320 Canoga Avenue, Woodland Hills, CA 91367 (US).			
(54) Title: INFUSION PUMP AND GLUCOSE SENSOR ASSEMBLY			
(57) Abstract <p>An infusion pump system (10) includes a removable <i>in vivo</i> glucose sensor (16) for monitoring glucose concentration level in a patient (12), and for signaling an infusion pump to deliver a selected medication such as insulin to a patient. The glucose sensor (16) comprises a sensor cable (30) for placement through a catheter to position a distal sensor tip (20) at a selected <i>in vivo</i> sensor site. A proximal end of the sensor cable seats within a connector fitting (18) mounted on the catheter (24) at a convenient and accessible subcutaneous position. The connector fitting (18) couples the sensor cable (30) to an implanted control unit (26) which signals the infusion pump (14) to deliver the patient (12) medication. In a preferred system, the infusion pump (14) is also implanted and receives control signals via a direct or telemetric connection. The sensor cable (30) is easily accessed at the connector fitting (18) for periodic sensor removal and replacement, without requiring removal or replacement of other system components.</p>			



**BEST AVAILABLE COPY**

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

-1-

## INFUSION PUMP AND GLUCOSE SENSOR ASSEMBLY

### BACKGROUND OF THE INVENTION

This invention relates generally to infusion pump systems for programmed operation to deliver a selected medication to a patient, particularly of the type including an infusion pump implanted directly into the body of the patient. More specifically, this invention relates to an improved system having an implanted glucose sensor adapted for convenient sensor removal and replacement on a periodic basis.

Medication infusion pumps are generally known in the art for use in delivering a selected medication to a patient in a scheduled or preprogrammed manner. In recent years, such infusion pumps have been developed in compact form adapted for direct implantation into the body of a patient, and to deliver a specific medication such as insulin to the patient in discrete doses over an extended time period. An implanted infusion pump of this general type includes an internal medication chamber for receiving and storing a supply of the selected medication in liquid form, in combination with miniature pump means and associated programmable control means for delivering the medication to the patient in accurate and repeatable doses. For one illustrative example of an implanted medication

-2-

infusion pump of this general type, see U.S. Patent 4,573,994.

While implantable infusion pumps have constituted a major step forward in reliable and convenient administration of certain medications, particularly insulin for a diabetic patient, practical programmed pump operation has been limited to an open loop approach involving medication dispensing in response to anticipated patient requirements. In this regard, implanted pumps have been adapted to deliver incremental doses at predetermined times and amounts in accordance with the condition and lifestyle of a particular patient. External controller devices have been developed for altering the pump program and/or for delivering a medication dose on demand, typically via a radio telemetry connection with the implanted pump. By contrast, a closed loop system involving controlled pump operation in response to actual rather than anticipated patient medication requirements, has not been available.

In recent years, considerable research and development activity has focused upon improvements in glucose sensors for monitoring glucose concentration level in a patient fluid, such as blood. These research efforts have resulted in proposals for implanted or in vivo glucose sensors designed to provide an instantaneous reading of patient glucose concentration. For examples of proposed in vivo glucose sensors, see U.S. Patents 4,650,547; 4,671,288; 4,781,798; 4,703,756; and 4,890,620.

The availability of implantable glucose sensors enhances the feasibility of a closed loop infusion pump system wherein operation of a medication infusion pump is responsive to actual glucose concentration measurements obtained on a continuous or frequent basis. However, the service life of an implantable glucose sensor is typically

-3-

relatively short in duration, on the order of a few months, whereas current infusion pump technology provides implantable components having an operating life on the order of ten years or more. A practical system designed to accommodate periodic removal and replacement of an in vivo glucose sensor, without requiring removal or replacement of other pump system components, has not been developed.

The present invention overcomes the problems and disadvantages encountered in the prior art by providing an improved infusion pump system adapted for closed loop control in response to operation of an implanted and easily removable glucose sensor.

#### SUMMARY OF THE INVENTION

In accordance with the invention, an infusion pump system includes a medication infusion pump for programmed operation to deliver a selected medication to a patient, in combination with an implantable glucose sensor for closed loop control of pump operation. In the preferred form, the infusion pump is also implanted within the body of the patient and is controlled automatically in response to glucose concentration measurements, by means of a direct or telemetric coupling with the sensor. The sensor is anchored within the patient by a subcutaneously mounted and easily accessed connector fitting having means for coupling or relaying sensor signals to the infusion pump. The glucose sensor is accessed at the connector fitting for relatively simple removal and replacement on an as-needed periodic basis, without requiring removal or replacement of other pump system components.

A preferred connector fitting has a generally cylindrical configuration adapted for convenient mounting beneath the patient's skin at a proximal end of a catheter leading to a selected in

-4-

vivo sensor site. The glucose sensor comprises an elongated sensor cable for placement through the connector fitting and catheter to position a sensor tip at a distal end of the cable substantially at the sensor site. A proximal end of the sensor cable seats within the connector fitting and includes means such as contacts or the like for coupling with the connector fitting so that the connector fitting provides means for electrically coupling the sensor cable to the pump system. In one preferred form, the connector fitting couples the sensor cable to an implantable control unit having means for telemetering sensor measurements to the infusion pump. In another form, the connector fitting is coupled directly to the infusion pump having the control unit integrated therein for regulating pump operation.

Other features and advantages of the present invention will become more apparent from the following detailed description, taken in conjunction with the accompanying drawings which illustrate, by way of example, the principles of the invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings illustrate the invention. In such drawings:

FIGURE 1 illustrates, somewhat in schematic form, a closed loop infusion pump system embodying the novel features of the invention for delivering a selected medication to a patient;

FIGURE 2 is an enlarged fragmented sectional view depicting a subcutaneously mounted connector fitting for use in the infusion pump system;

FIGURE 3 is an enlarged fragmented sectional view similar to FIG. 2, and depicting a glucose sensor cable installed within the connector fitting; and

-5-

FIGURE 4 is a schematic view similar to FIG. 1, but depicting an alternative preferred form of the invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

As shown in the exemplary drawings, a closed loop infusion pump system referred to generally in FIGURE 1 by the reference numeral 10 is provided for delivering a selected medication to a patient 12. The system 10 generally comprises an infusion pump 14 which responds to control signals from an implantable sensor unit 16 to deliver the medication as needed to the patient. In accordance with a primary aspect of the invention, the sensor unit 16 includes a subcutaneously mounted connector fitting 18 for anchoring an in vivo glucose sensor 20 in a manner permitting convenient sensor removal and replacement.

The improved infusion pump system 10 of the present invention monitors patient glucose concentration level on a continuous or frequent intermittent basis to provide appropriate control signals for closed loop control of the infusion pump 14. The selected medication such as insulin for a diabetic patient may thus be administered to the patient in response to actual patient requirements as represented by the glucose measurement. The connector fitting 18 provides a relatively simple and easily accessed structure for coupling the glucose sensor 20 with other system components, while permitting access to the glucose sensor for removal and replacement. In this regard, the glucose sensor 20 can be replaced on a periodic basis, typically at the conclusion of a service life of a few months, while permitting the remaining system components to remain undisturbed within the patient.

-6-

In a preferred system arrangement as viewed in FIG. 1, the infusion pump 10 comprises a small and substantially self-contained unit adapted for direct implantation into the body of the patient 12. The pump 14 comprises an hermetically sealed pump housing constructed typically from a biocompatible material such as titanium to titanium alloy, and defining an internal medication chamber for receiving and storing a supply of the selected medication in liquid form, such as insulin for a diabetic patient. The pump housing further encases a miniature dispensing pump and associated electronic control circuitry in combination with a battery power supply for operating the pump to deliver medication doses to the patient via an appropriate catheter 22 or the like. The control circuitry is suitably programmed and operated to deliver the medication in accordance with individual patient need, including but not limited to closed loop response to glucose concentration measurement as will be described in more detail. In addition, the pump housing is designed to permit percutaneous refilling of the internal medication chamber without requiring surgical access to the implanted pump. For a more detailed description of the overall construction and operation of implantable infusion pumps of this general type, see U.S. Patents 4,373,527 and 4,573,994, which are incorporated by reference herein.

The sensor unit 16 is also implanted within the patient 12 at a selected position for placement of the glucose sensor 20 in contact with a patient fluid, such as in intimate contact with patient blood within a cephalic vein. The sensor unit 16 generally comprises the connector fitting 18 mounted at proximal end of an elongated catheter 24 (FIG. 2). The connector fitting 18 is located at a convenient subcutaneous site for relatively easy palpable identification, whereas the catheter 24 extends from

-7-

the connector fitting to a distal end positioned at a selected in vivo sensor position. A telemetry unit 26 (FIG. 1) is coupled to the connector fitting 18 and functions to transmit glucose measurement signal information by means of radio telemetry. As viewed in FIG. 1, the telemetry unit 26 can transmit the glucose measurement information to the infusion pump 14 for closed loop operation thereof, or alternately to an externally located monitor 28. FIG. 1 illustrates the monitor 28 in the form of a wrist-worn device, although it will be understood that the monitor 28 may take other convenient forms. As is known in the art, the monitor 28 can be manipulated in response to information received and/or displayed thereby to control pump operation through the use of radio telemetry signals. In this regard, the monitor 28 may be programmed to automatically adjust pump operation according to glucose measurements, or to recommend a treatment program to allow patient verification and manual initiation, or to simply display the glucose readings and permit manual entry of reprogramming commands.

The glucose sensor 20 generally comprises, in one preferred form, an implantable enzyme electrode of the general type described in U.S. Patents 4,650,547; 4,671,288; 4,781,798; 4,703,756; and 4,890,620 which are incorporated by reference herein. Such enzyme electrodes comprise an elongated sensor cable 30 (FIGS. 1 and 3) having a distal end defining a sensor tip for direct contact with patient fluid, such as blood. The sensor tip defines a conductivity sensor for measuring fluid conductivity changes in response to an enzymatic reaction typically involving the use of glucose oxidase to catalyze glucose in the presence of oxygen ( $O_2$ ). Conductivity signals are transmitted through the cable via conductors 34 to a proximal end of the sensor cable.

-8-

As shown in FIGS. 2 and 3, the connector fitting 18 provides a convenient and relatively simple structure for anchoring the proximal end of the sensor cable 30 in electrical coupled relation with the telemetry unit 26. More particularly the illustrative connector fitting 18 is mounted at the proximal end of the catheter 24 and has a generally cylindrical shape defining a central bore 36 disposed in-line with the catheter. The sensor cable 30 may thus be introduced percutaneously for passage through the connector fitting 18 and catheter 24 to position the sensor tip 32 at the in vivo sensor site. In this position, the proximal end of the sensor cable 30 is seated and retained within the connector fitting (FIG. 3).

The connector fitting 18 includes a radially enlarged flange 38 having suture ports 40 formed therein to facilitate anchored connection of the fitting by sutures 42 or the like to the subcutaneous muscle facia. An internal key 44 within the connector fitting 18 aligns with a mating key slot 46 in the sensor cable 30 to rotationally orient cable contacts 48 with mating contacts 50 within the connector fitting. An external lock ring 52 is conveniently provided for radially compressing the connector fitting 18 in the vicinity of the contacts 48 and 50 to ensure intimate electrical connection. The fitting contact 50 are connected in-turn via internal conductors 54 to an appropriate cable 56 leading to the telemetry unit 26. It will be understood, however, that alternative couplings may be provided for interconnecting the sensor with the connector fitting.

FIGURE 4 illustrates an alternative preferred form of the invention, wherein the cable 56 connected to the fitting 18 is connected directly to a control unit or circuit disposed internally within

-9-

the implanted pump 14. With this system, radio telemetry transfer of glucose measurement information to the pump 14 is unnecessary. Instead, the information is transmitted directly through the use of the cable 56. Once again, the external monitor 28 may be used to read out or reprogram the pump 14 as previously described.

In either embodiment, the glucose sensor 20 can be accessed quickly and easily for periodic replacement. In this regard, the service life of the glucose sensor 20 is typically on the order of a few to several months, for a service period substantially less than the service life of an implanted pump 14. When sensor replacement is required, the sensor cable 30 is accessed through the skin of the patient for relatively easy sensor removal and insertion of a replacement sensor cable. Importantly, sensor removal and replacement is accomplished under the influence of a local anesthetic, and without requiring removal or replacement of any other system components.

A variety of further modifications and improvements to closed loop infusion pump system will be apparent to those persons skilled in the art. For example, it will be understood that the implanted sensor unit with removable sensor 20 can be used to provide glucose measurement information to an external monitor, and/or to an external pump. Moreover, the connector fitting may be provided as part of an integrated unit including the pump 14, whereby the sensor is disconnectable from the pump for removal and replacement, if desired. Accordingly, no limitations on the invention are intended by way of the foregoing description and accompanying drawings, except as set forth in the appended claims.

-10-

WHAT IS CLAIMED IS:

1. A system for delivering medication to a patient, comprising:

a sensor unit including implantable sensor means for in vivo monitoring of a patient parameter, an implantable connector fitting for removably supporting said sensor means within a patient to permit transcutaneous access to said sensor means for removal and replacement without removing said connector fitting from the patient, and control means coupled by said fitting to said sensor means for generating a signal representative of the monitored patient parameter; and

pump means for administering medication stored therein to the patient, said pump means including means responsive to said signal to administer the medication in accordance with the monitored patient parameter.

2. The system of claim 1 wherein said control means is implantable.

3. The system of claim 1 wherein said pump means is implantable.

4. The system of claim 1 wherein said pump means and said control means are implantable.

5. The system of claim 1 wherein said signal comprises a radio telemetry signal.

6. The system of claim 1 wherein said sensor means comprises a glucose sensor.

-11-

7. The system of claim 1 wherein said sensor means comprises a sensor cable having a sensor tip at a distal end thereof, and a proximal end for removable mounting within said connector fitting.

8. The system of claim 7 further including a catheter having one end connected to said fitting and adapted to extend from said fitting generally to a selected in vivo sensing site within the patient, said sensor cable extending from said fitting through said catheter.

9. The system of claim 7 wherein said fitting has a generally cylindrical shape for receiving said cable proximal end.

10. The system of claim 9 further including compression means for retaining said cable proximal end within said fitting.

11. The system of claim 1 further including means for securing said fitting at a selected subcutaneously position within the patient.

12. A system for delivering medication to a patient, comprising:

a sensor unit including sensor means for monitoring of a patient parameter, and control means coupled to said sensor means for generating a signal representative of the monitored patient parameter; and

implantable pump means for administering medication stored therein to the patient, said pump means including means responsive to said signal to administer the medication in accordance with the monitored patient parameter.

-12-

13. The system of claim 12 wherein said sensor unit is implantable.

14. The system of claim 12 wherein said sensor means comprises a glucose sensor.

15. The system of claim 12 wherein said sensor means is removably mounted in vivo.

16. The system of claim 12 wherein said signal comprises a radio telemetry signal.

17. The system of claim 12 wherein said signal is connected directly to said pump means.

18. A system for delivering medication to a patient, comprising:

a sensor unit including sensor means for in vivo monitoring of a patient parameter, and control means coupled to said sensor means for generating a radio telemetry signal representative of the monitored patient parameter; and

pump means for administering medication stored therein to the patient, said pump means including means responsive to said signal to administer the medication in accordance with the monitored patient parameter.

19. The system of claim 18 wherein said control means is implantable.

20. The system of claim 18 wherein said pump means is implantable.

21. The system of claim 18 wherein said sensor means comprises a glucose sensor.

-13-

22. The system of claim 21 wherein said glucose sensor is a subcutaneous glucose sensor.

23. The system of claim 18 further including an implantable connector fitting for removably supporting said sensor means within a patient to permit transcutaneous access to said sensor means for removal and replacement without removing said connector fitting from the patient.

24. The system of claim 18 including a monitor disposed externally of the patient, said monitor including means for receiving said radio telemetry signal and for responding thereto by radio telemetry to control operation of said pump means.

25. The system of claim 24 wherein said monitor includes means for displaying information in response to said radio telemetry signal.

26. The system of claim 24 wherein said monitor includes means for mounting thereof onto the patient.

27. A system for delivering medication to a patient, comprising:

a subcutaneous glucose sensor for in vivo monitoring of blood glucose level in a patient;

means coupled to said sensor for generating a radio telemetry signal representative of blood glucose level in the patient; and

a medication infusion pump including means responsive to said radio telemetry signal to deliver a selected medication to the patient.

-14-

28. The system of claim 27 wherein the pump is implantable.

29. The system of claim 31 wherein said monitor includes means for displaying information in response to said radio telemetry signal.

30. The system of claim 21 wherein said monitor includes means for mounting thereof onto the patient.

31. The system of claim 27 further including a monitor disposed externally of the patient, said means coupled to said sensor being for generating a first radio telemetry signal representative of blood glucose level in the patient, said monitor including means for receiving said first radio telemetry signal and for responding thereto to generate a second radio telemetry signal, said telemetry signal responsive means of said pump comprising means responsive to said second radio telemetry signal to deliver the selected medication to the patient.

1/2

FIG. 1





FIG. 2



2/2




FIG. 3




FIG. 4

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/04824

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61B 5/05; A61M 31/00  
 US CL :128/635; 604/67

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 128/632, 635, 637, DIG.13; 604/50, 65-67

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS:

Search Terms: glucose sensor, radio telemetry, implanted

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y	US, A, 4,543,955 (SCHROEPPEL) 01 October 1985, see figures 1-5.	1, 5, 7, 9, 12, 13, 15-20, 23 ----- 6, 8, 10, 11, 14, 21, 22, 24- 31
Y	US, A, 4,538,616 (ROGOFF) 03 September 1985, see entire document.	6, 8, 14, 21, 22, 27-31
Y	US, A, 4,985,015 (OBERMANN ET AL.) 15 January 1991, see entire document.	24-26, 29-31



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*'A'		document defining the general state of the art which is not considered to be part of particular relevance
*'E'	"X"	earlier document published on or after the international filing date
*'L'	"Y"	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
*'O'		document referring to an oral disclosure, use, exhibition or other means
*'P'	"&"	document published prior to the international filing date but later than the priority date claimed

Date of the actual completion of the international search  
  
01 JUNE 1995

Date of mailing of the international search report

28 JUN 1995

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231  
Facsimile No. (703) 305-3230Authorized officer  
CHALIN SMITH  
Telephone No. (703) 308-2988*Stacia Sinuk  
for*

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/04824

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US, A, 5,174,291 (SCHOONEN ET AL.) 29 December 1992, see entire document.	1-31
A	US, A, 4,822,337 (NEWHOUSE) 18 April 1989, see entire document.	1-31

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**